These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients. Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672 [TBL] [Abstract][Full Text] [Related]
30. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374 [TBL] [Abstract][Full Text] [Related]
31. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report. Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412 [TBL] [Abstract][Full Text] [Related]
32. Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder. Rapoport JL; Inoff-Germain G Neurol Clin; 1997 May; 15(2):421-8. PubMed ID: 9115472 [TBL] [Abstract][Full Text] [Related]
33. Current and potential pharmacological treatments for obsessive-compulsive disorder. Davidson J; Bjorgvinsson T Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603 [TBL] [Abstract][Full Text] [Related]
34. The potential of vortioxetine in treating obsessive-compulsive disorder. Biswas T Asian J Psychiatr; 2023 Apr; 82():103460. PubMed ID: 36681041 [No Abstract] [Full Text] [Related]